<SEC-DOCUMENT>0001493152-21-003076.txt : 20210209
<SEC-HEADER>0001493152-21-003076.hdr.sgml : 20210209
<ACCEPTANCE-DATETIME>20210209163211
ACCESSION NUMBER:		0001493152-21-003076
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210209
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210209
DATE AS OF CHANGE:		20210209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NTN BUZZTIME INC
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		21606947

	BUSINESS ADDRESS:	
		STREET 1:		6965 EL CAMINO REAL
		STREET 2:		SUITE 105-BOX 517
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92009
		BUSINESS PHONE:		7604387400

	MAIL ADDRESS:	
		STREET 1:		6965 EL CAMINO REAL
		STREET 2:		SUITE 105-BOX 517
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d) of the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of report (Date of earliest event reported): <B>February 9, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>NTN
BUZZTIME, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-11460</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>31-1103425</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
        or other jurisdiction of</FONT></P>
        <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation)</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></P>
        <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
        Number)</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
        Employer</FONT></P>
        <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
        No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6965
    El Camino Real, Suite 105-Box 517</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carlsbad,
    California</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92009</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(760)
438-7400</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&rsquo;s
telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
Applicable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<I>see</I> General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NTN</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NYSE
    American</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).
Emerging growth company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    8.01</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
    Events.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 9, 2021, Brooklyn ImmunoTherapeutics LLC (&ldquo;Brooklyn&rdquo;) issued a press release announcing, among other matters,
the initiation of an open-label Phase 2 clinical trial of IRX-2 in combination with pembrolizumab (Keytruda&reg;) and chemotherapy
in triple negative breast cancer (TNBC). A copy of the press release is attached as an exhibit to this report and is incorporated
herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously announced, on August 12, 2020, NTN Buzztime, Inc. (&ldquo;NTN&rdquo;) entered into an Agreement and Plan of Merger
and Reorganization with Brooklyn and BIT Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of NTN (&ldquo;Merger
Sub&rdquo;), pursuant to which, subject to the satisfaction of the conditions to closing, Merger Sub will be merged with and into
Brooklyn, with Brooklyn surviving the merger as a wholly-owned subsidiary of NTN. NTN will be holding its special meeting of stockholders
to consider the merger, and the proposed sale of NTN&rsquo;s assets to eGames.com Holdings LLC (&ldquo;eGames.com&rdquo;) and
related proposals on March 15, 2021 at 9:00 a.m., Pacific Time, unless postponed or adjourned to a later date or time. Additional
details regarding the proposals and the special meeting are available in the proxy statement/prospectus/consent solicitation statement
relating to the special meeting that was filed with the Securities and Exchange Commission on February 8, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    9.01</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
    Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</FONT></TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Press release issued by Brooklyn ImmunoTherapeutics LLC dated February 9, 2021</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No
Offer or Solicitation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
release is not intended to and shall not constitute an offer to sell or the solicitation of an offer to buy any securities or
the solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer
of securities in connection with the proposed merger contemplated by the agreement and plan of merger and reorganization between
NTN and Brooklyn dated August 12, 2020 shall be made except by means of a prospectus meeting the requirements of Section 10 of
the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Additional
Information and Where to Find It</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the proposed merger and asset sale, NTN filed relevant materials with the SEC, including a registration statement
on Form S-4, that will serve as a proxy statement and prospectus of NTN and a consent solicitation statement for the beneficial
holders of Brooklyn&rsquo;s Class A membership units, and will be mailed or otherwise disseminated to NTN stockholders and to
the beneficial holders of Brooklyn&rsquo;s Class A membership units if and when it becomes available. INVESTORS AND SECURITY HOLDERS
OF NTN AND BROOKLYN ARE URGED TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT NTN, BROOKLYN, THE PROPOSED MERGER AND ASSET SALE, AND RELATED MATTERS. The proxy
statement/prospectus/consent solicitation statement and other relevant materials (when they become available) and any other documents
filed by NTN with the SEC, may be obtained free of charge at the SEC website at www.sec.gov. In addition, investors and security
holders may obtain free copies of the documents filed with the SEC by NTN by directing a written request to: NTN Buzztime, Inc,
6965 El Camino Real, Suite 105-Box 517, Carlsbad, California 92009. Investors and security holders are urged to read the proxy
statement/prospectus/consent solicitation statement and the other relevant materials when they become available before making
any voting or investment decision with respect to the proposed merger and asset sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Participants
in the Solicitation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NTN
and its directors, executive officers and certain other members of management and employees, Brooklyn and its managers and officers,
and eGames.com and its managers and officers may, under SEC rules, be deemed to be participants in the solicitation of proxies
from the stockholders of NTN with respect to the proposed merger and asset sale and related matters. Information about the directors
and executive officers of NTN, including their ownership of shares of common stock is set forth in NTN&rsquo;s Annual Report on
Form 10-K for the year ended December 31, 2019 and Amendment No. 1 thereto, which were filed with the SEC on March 19, 2020 and
April 27, 2020, respectively (the &ldquo;2019 Annual Report&rdquo;). Additional information regarding the persons or entities
who may be deemed participants in the solicitation of proxies from NTN stockholders, including a description of their interests
in the proposed merger and asset sale, by security holdings or otherwise, are included in the proxy statement/prospectus/consent
solicitation statement referred to above and other relevant documents to be filed with the SEC when they become available. As
described above, these documents will be available free of charge at the SEC&rsquo;s website or by directing a written request
to NTN. Neither the managers or officers of Brooklyn nor the managers or officers of eGames.com currently hold any interests,
by security holdings or otherwise, in NTN.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Forward-Looking
Statements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that are not statements
of historical fact and may be identified by terminology such as &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo;
&ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo;
&ldquo;could,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue,&rdquo;
or the negative of these terms or other similar words. Forward-looking statements are based on current beliefs and assumptions
that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially
from those stated or implied in any forward-looking statement as a result of various factors, including, but not limited to: (i)
risks that the conditions to the closing of the proposed merger and/or asset sale are not satisfied, including the failure of
NTN and Brooklyn to timely obtain the requisite stockholder and member approvals for the merger and/or asset sale and related
matters or to meet the net cash and capitalization requirements under the merger agreement, as applicable; (ii) uncertainties
as to the timing of the consummation of the proposed merger and asset sale and the ability of each party to consummate the proposed
merger and asset sale; (iii) risks related to NTN&rsquo;s and Brooklyn&rsquo;s ability to manage their respective operating expenses
and expenses associated with the proposed merger and asset sale, as applicable, pending closing of the merger; (iv) the risk that,
as a result of adjustments to the exchange ratio, NTN stockholders and Brooklyn members could own more or less of the combined
company than is currently anticipated; (v) NTN&rsquo;s continued listing on the NYSE American; (vi) uncertainties related to the
impact of the COVID-19 pandemic on the business and financial condition of NTN, Brooklyn and the combined company and the ability
of NTN and Brooklyn to consummate the merger and NTN and eGames.com to consummate the asset sale; (vii) NTN&rsquo;s ability to
continue to operate as a going concern if the proposed merger or asset sale are not consummated in a timely manner, or at all;
(viii) Brooklyn&rsquo;s need for, and the availability of, substantial capital in the future to fund its operations and research
and development activities; (ix) Brooklyn&rsquo;s ability to successfully progress research and development efforts after the
merger, including its manufacturing development efforts, and to create effective, commercially-viable products; (x) the success
of Brooklyn&rsquo;s product candidates in completing pre-clinical or clinical testing and being granted regulatory approval to
be sold and marketed in the United States or elsewhere; (xi) the outcome of any legal proceedings that have been instituted against
NTN, Brooklyn, eGames.com or others related to the merger agreement or the asset purchase agreement, as applicable; (xii) the
occurrence of any event, change or other circumstance or condition that could give rise to the termination of either or both of
those agreements; (xiii) potential adverse reactions or changes to business relationships resulting from the announcement or completion
of the proposed merger or asset sale; and (xiv) those risks and uncertainties discussed in NTN&rsquo;s reports filed with the
SEC, including its 2019 Annual Report, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K, as well as other
documents that may be filed by NTN from time to time with the SEC available at www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. NTN cannot assure you that the events and circumstances
reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected
in the forward-looking statements. The forward-looking statements made in this communication speak only as of the date on which
they were made. NTN does not undertake any obligation to update the forward-looking statements contained herein to reflect events
that occur or circumstances that exist after the date hereof, except as may be required by applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NTN
    BUZZTIME, INC.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    February 9, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><I>/s/
    Sandra Gurrola</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra
    Gurrola</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr.
    Vice President of Finance</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 77px; width: 300px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Brooklyn
ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Triple
Negative Breast Cancer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Brooklyn,
NY</B> &ndash; February 9, 2021 &ndash; Brooklyn ImmunoTherapeutics LLC (&ldquo;Brooklyn&rdquo;), a biopharmaceutical company
focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the initiation
of an open-label Phase 2 clinical trial of IRX-2 in combination with pembrolizumab (Keytruda<SUP>&reg;</SUP>) and chemotherapy
in triple negative breast cancer (TNBC). The trial will be conducted at the Providence Cancer Institute in Portland, Oregon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRX-2
is an allogeneic, cell-derived biologic with multiple active cytokine components, including IL-2, that act on various parts of
the immune system associated with activation of the entire tumor microenvironment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;In
a Phase 1b clinical trial in early stage breast cancer, IRX-2 was well-tolerated as a single agent with no Grade 3 or 4 toxicities
in patients and encouraging signs of activity including upregulation of PD-L1,&rdquo; said principal investigator David Page,
M.D., medical oncologist and assistant member, Earle A. Chiles Research Institute, a division of Providence Cancer Institute.
&ldquo;These results provide a strong rationale for studying IRX-2 in combination with pembrolizumab, an immunotherapy that targets
PD-1, and standard of care chemotherapy in triple negative breast cancer, a disease for which there is an urgent need for new
treatment options.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;IRX-2
is currently being studied in a range of cancer indications, both as a single agent and in combination with other anti-cancer
therapies, including checkpoint inhibitors,&rdquo; said Lynn Sadowski Mason, Executive Vice President, Clinical Operations of
Brooklyn ImmunoTherapeutics. &ldquo;We believe that the unique combination of cytokines in IRX-2 can improve outcomes for patients
with solid tumor cancers based on its ability to activate the immune system in the tumor microenvironment. We look forward to
the results of this clinical trial and to exploring potential new indications in the future.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the Phase 2 Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2 randomized, open-label trial is designed to assess the efficacy and safety of IRX-2 in patients with TNBC. Approximately
30 patients in total are expected to be enrolled. Patients with locally confirmed TNBC who have previously untreated locally advanced
non-metastatic TNBC are eligible. Patients will receive alternating regimens of Pembrolizumab plus chemotherapy and subcutaneous
IRX-2 injections twice a day for 10 days as neoadjuvant therapy prior to surgery. The primary efficacy endpoint is pathological
Complete Response (pCR) and patients will be evaluated following definitive surgery. Please refer to <U>www.clinicaltrials.gov
</U>(NCT04373031) for additional clinical trial details.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study is supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp &amp; Dohme
Corp., a subsidiary of Merck &amp; Co., Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Brooklyn ImmunoTherapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brooklyn
ImmunoTherapeutics is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both
as a single agent and in combination with other anti-cancer therapies. Our most advanced program is studying the safety and efficacy
of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall
survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications. For more information
about the company and its clinical programs, please visit <U>www.BrooklynITx.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Providence Cancer Institute</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providence
Cancer Institute, a part of Providence St. Joseph Health, offers the latest in cancer services, including diagnostic, treatment,
prevention, education, support and internationally renowned research. Providence Cancer Institute is home to the Earle A. Chiles
Research Institute, a world-class research facility located within the Robert W. Franz Cancer Center in Portland, Oregon, and
is a recognized leader in the field of cancer immunotherapy since 1993. To learn more, visit <U>www.providenceoregon.org/cancer</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Information and Where to Find It</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brooklyn
has entered into a merger agreement with NTN Buzztime, Inc. (&ldquo;NTN&rdquo;), and in connection therewith, NTN has filed a
registration statement on Form S-4 to register the shares to be issued to Brooklyn&rsquo;s members at the effective time of the
merger. The Form S-4 registration statement has become effective, and investors are urged to read these materials carefully and
in their entirety because they contain important information about the merger, Brooklyn&rsquo;s business, its clinical trials,
and related matters. Copies of the proxy statement/prospectus/consent solicitation statement and other relevant materials may
be obtained free of charge at the SEC website at www.sec.gov. In addition, investors and security holders may obtain free copies
of the documents filed with the SEC by directing a written request to: Brooklyn Immunotherapeutics LLC, 140 58<SUP>th</SUP> Street,
Building A, Suite 2100, Brooklyn, NY 11220.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that are not statements
of historical fact and may be identified by terminology such as &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo;
&ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo;
&ldquo;could,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue,&rdquo;
or the negative of these terms or other similar words. Forward-looking statements are based on current beliefs and assumptions
that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially
from those stated or implied in any forward-looking statement as a result of various factors, including, but not limited to: (i)
risks that the conditions to the closing of the proposed merger between Brooklyn and NTN will not be satisfied; (ii) uncertainties
related to the impact of the COVID-19 pandemic on the business and financial condition of Brooklyn, including on the timing and
cost of the BR-202 clinical trial; (iii) whether the BR-202 trial will be successful; (iv) whether IRX-2 will ever be approved
for commercialization by the U.S. Food &amp; Drug Administration, and (v) those other factors set forth in the proxy statement/prospectus/consent
solicitation statement. You should not rely upon forward-looking statements as predictions of future events. Brooklyn cannot assure
you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results
could differ materially from those projected in the forward-looking statements. The forward-looking statements made in this communication
speak only as of the date on which they were made, and Brooklyn does not undertake any obligation to update the forward-looking
statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as may be required
by applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">###</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MacDougall</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nicholas
Chang</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>nchang@macbiocom.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">781-235-3060</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "9 E@# 2(  A$! Q$!_\0
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MX,U2XUR?5WLC(-5N%@+W9B'E9!7: P!')P:ZN*P\#1Z+)I"W5@;!GWF%[[<
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M>$?!]&?Q;=!9'C_T%^5 _OIZ@U[?]GEQ_P ?D_Y)_P#$UX.-_C,]O _P3EO
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MTK7/./!>J:C!_;_DZ#=W._6+AWV30KY;';E#N<9(]1D>]=3_ &WK'_0K7_\
MX$V__P <K-\ ]/$O/_,>NO\ V6NPYK&<US;?F:THOD6IPGB_5M3F\(:I'-X=
MO((V@8-*\\!"CU(5R?R%6] U?5(_#NF)'X;O946TB D6X@ 8;!R 9,\^]7_'
M7_(C:Q_U[-5SPU_R*VD?]>4/_H I\R]GMU$HOVF_0XWQEJ>HS'0/.T&\M]FL
M6[IOFA;S&&["#:YP3ZG ]374#6]8Q_R*U_\ ^!-O_P#'*SO'O_,M?]AVU_\
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M8*%*7-NS&MBYU5R[!7TAX"TJ31_!EA;3)LG=#-*,$$%R6 (/< @'Z5Y=\._
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MO^O9?_0FJC:%;?PCJ$I9MUS<1P  =-OSY_$$BNYUCPQ9ZS>+<W$TZ.J! (V
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M&KH0RL 01W%<VS,_@L%B20 .?028'Z5N:;_R"[3_ *XI_(52E=DM6'1WEO+
M\\<JM$F=S \# R:@FU>PMB%EN4!(R N6X[=,UCZ1_P BU?\ _;3_ - %6M#L
M+272(I'MXG=RQ)=0QZD=_I4J4G:Q3BEN;44L<\2R1.KHW1E.0:JW.JV5I)Y<
M]PJMW !)'UQTK.\/CR[K4H$R(HY<(N>G+#^@_*HO#]K!=VL]Q<PI-*TQRTBA
MNP/?ZFCG;2L+E2O<VX9[>\@+PNLD;#!P?T]JQ=7TBPM=*FFA@V2+MP=[''S
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M.3ZGN0BHQ45T"BBB@H**** "BBB@ HHHH **** "BBHY)8X4+R.J(.K,< 4
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MR3G&YL?EG%.47>Z%%JUF9>ED'0-3*C"GS,#_ (#5K0;VU328HWGC1XRP968
MCDG^M7+JVAMM+O1!&J!XG8A>!G;CIVK.TC2;&\TJ":> ,Y# D,1GYCZ&H2E&
M22*;33;)-%=9M3U.6,YC+@!AT/6JNA+9)#/!>K )TE.1*!G& ._N#70P6T-I
M$(H(PB#L/\\U7N=(L;R7S9X TA&"P8C/Y&JY'9"YD4[*YA?6YK>U@MA"D>?-
MC09)XXR/K^E0:9-'::QJ44[K&\DFY0QQD9)_D16Q:6-O9)L@B5 >N.I^IIEW
MIMG>LK7$(=E& <D''X4<LM'U%S+8RY[B*?Q/9>5(K[4()4Y .&XIWB [+O39
MWR(HYOF;'3E3_0_E6A#I5E;E&BMU5D;<K9.<XQUZ_A5J6&.>)HY4#HW52*.1
MM.X<RNA(;F"<-Y$T<FWKL8''Y5B>&E+Z-<*.K2,!_P!\BM6UL+6QW_9HMA?&
M[YB<X^I]Z=:6<%E$8H(]B%MV,D\_C]*KE;:;%=),R_#][;II:Q23(CHS AV
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MB W(Z^M>@5PMC_R$;;_KJO\ ,5W5=-%61S5MQ:***W,@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"-T61&1U#*PP0
M>XI(HHX(A'$BH@Z*HP!4M% !1110 4444 %%%% !1110 4444 %%%% !1110
? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
